The Top LineThe Top Line

Breaking down the 55 new drug approvals of 2024

View descriptionShare

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these firms are bringing to the market.

In this week’s episode of “The Top Line,” we take a deep dive into the FDA’s list of drugs that were approved in 2024. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss why biotechs emerged with more approvals than large drugmakers and which new drugs figure to have the most impact for patients.

To learn more about the topics in this episode:

 

This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.

  • Facebook
  • X (Twitter)
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. The Top Line

    151 clip(s)

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fie 
Social links
Follow podcast
Recent clips
Browse 154 clip(s)